Dilok Klaisataporn Most major stock indexes across the globe ended the week lower, following US-China trade talks and renewed ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Novo Nordisk is progressing both subcutaneous and ... will receive approval for adults with overweight or obesity in Q4 2030 in the US, followed by approval in the EU in Q1 2031.

Hims & Hers Health, Inc. sees 38% YoY subscriber growth, driven by 70% choosing personalized treatments. Click for my updated ...

For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the ...

The stock market heads into the final week of June with an eye on Tesla, Novo Nordisk, defense stocks and weekly jobless ...

Phase 2a data on Skye Bioscience's (NASDAQ:SKYE) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, should be ...

Wednesday marked a losing session on Wall Street, with the S&P 500 snapping its three-day win streak, as did the Nasdaq ...

Indian benchmarks traded mixed as profit booking in financial stocks countered optimism from U.S.-China trade talks and ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...